Indeed, Tocilizumab, an anti-IL-6R monoclonal antibody, in combination with chemotherapy, has shown an acceptable safety profile and a possible immunological benefit in patients with advanced ovarian cancer in a phase I trial17. Here, IL6R is linked to ovarian carcinoma.